AKR1C1 and urinary bladder carcinoma: As shown in Figure 2H,I, the expression levels of AKR1C1 in the recurrent bladder cancer foci of seven of eight patients were significantly higher than that in the primary focus, and only one patient had no significant difference between the expression of AKR1C1 in the recurrent and the primary focus.